{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022\\\/medrxiv\\\/early\\\/2021\\\/04\\\/26\\\/2021.04.25.21255903.atom\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022\u0022,\u0022apath\u0022:\u0022\\\/medrxiv\\\/early\\\/2021\\\/04\\\/26\\\/2021.04.25.21255903.atom\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022},\u0022medrxiv;2021.04.25.21255903v1\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2021.04.25.21255903v1\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022abstract\u0022,\u0022variant\u0022:\u0022abstract\u0022,\u0022view\u0022:\u0022abstract\u0022,\u0022pisa\u0022:\u0022medrxiv;2021.04.25.21255903v1\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__uXgUByez87OKDsgffPHe7u5qNUzr7zOnqWrSJ87THKk__I8zmferlWQG1DHWX_fZmeyRd733gqStwZcOGe0mM0T4__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-biorxiv-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article abstract-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EABSTRACT\u003C\/h2\u003E\u003Cdiv id=\u0022sec-1\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-5\u0022\u003E\u003Cstrong\u003EIntroduction\u003C\/strong\u003E Progress achieved by long-lasting insecticidal nets (LLINs) against malaria is threatened by the widespread selection of pyrethroid resistance among vector populations. LLINs with non-pyrethroid insecticides are urgently needed. This study aims to assess the durability of three novel dual active ingredient LLINs and to parameterise a mathematical model to predict epidemiological outcomes of these products for malaria vector control.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-2\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-6\u0022\u003E\u003Cstrong\u003EMethods\u003C\/strong\u003E A WHO Phase 3 active ingredients and textile durability study will be carried out within a cluster randomised controlled trial in Misungwi district in 40 clusters. The following treatments will be evaluated; 1\/ Interceptor G2\u00ae combining chlorfenapyr and a pyrethroid alpha-cypermethrin, 2\/ Royal Guard\u00ae treated with pyriproxyfen and alpha-cypermethrin and 3\/ Olyset\u2122 Plus which incorporates a synergist piperonyl butoxide and the pyrethroid permethrin, and 4\/ a reference standard pyrethroid-only LLIN (Interceptor\u00ae). 750 nets will be followed in 5 clusters per intervention arm at 6, 12, 24 and 36 months post distribution for survivorship and hole index assessment. A second cohort of 1950 nets per each type will be identified in 10 clusters, of which 30 LLINs will be withdrawn for bio-efficacy and chemical analysis every 6 months up to 36 months and another 30 collected for an experimental hut trial study every year. Bio-efficacy will be assessed using cone bioassays and tunnel tests against susceptible and resistant laboratory strains of \u003Cem\u003EAnopheles gambiae\u003C\/em\u003E sensu stricto. Efficacy of field collected nets will be compared in six experimental huts. The main outcomes will be \u003Cem\u003EAnopheles\u003C\/em\u003E mortality up to 72 hours post exposure, blood feeding and egg maturation using ovary dissection to assess impact on fecundity.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-7\u0022\u003E\u003Cstrong\u003EEthics and dissemination\u003C\/strong\u003E Ethical approval was received from the Tanzanian ethics review committee as well as from each institution. Study findings will be disseminated via reports and presentations to national and international stakeholders, conferences, and peer-reviewed publications.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-8\u0022\u003E\u003Cstrong\u003ETrial registration number\u003C\/strong\u003E NCT03554616\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-5\u0022 class=\u0022subsection\u0022\u003E\u003Cdiv id=\u0022sec-6\u0022 class=\u0022subsection\u0022\u003E\u003Cp\u003E\u003Cstrong\u003EStrengths of this study\u003C\/strong\u003E\u003C\/p\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-1\u0022\u003E\u003Cli id=\u0022list-item-1\u0022\u003E\u003Cp id=\u0022p-9\u0022\u003EThis is the first study assessing the durability of these novel dual-A.I. LLINs over three years alongside a cluster randomised controlled trial (cRCT).\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-2\u0022\u003E\u003Cp id=\u0022p-10\u0022\u003EThe study will support the development of bio-efficacy and physical durability criteria of performance for the partner A.I. in relation to the cRCT efficacy outcomes and refine preferred product characteristics developed by the WHO.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-3\u0022\u003E\u003Cp id=\u0022p-11\u0022\u003EAn experimental hut trial done in the vicinity of the cRCT, with similar vector population characteristics and using nets sampled from the main trial will allow us to understand the impact of field conditions, wear-and-tear and insecticidal deterioration on the efficacy of the dual-A.I. LLINs on entomological outcomes and relate these to the cRCT epidemiological and entomological outcomes.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-4\u0022\u003E\u003Cp id=\u0022p-12\u0022\u003EAll other products falling under these novel dual-A.I. LLINs classes will be assessed according to those criteria alongside non-inferiority studies in experimental huts and modelling of these data.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-7\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-13\u0022\u003E\u003Cstrong\u003ELimitations of this study\u003C\/strong\u003E Potential limitations include 1\/ the net loss of follow up used to calculate sample size, which was taken from another study site and might differ in Misungwi, and 2\/ the experimental hut site is situated in the northern section of the cRCT study area and may not represent vector species composition of the southern section of the cRCT.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022kwd-group Author\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EBio-efficacy\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Etextile durability\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Emalaria vectors\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Einsecticide resistance\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ERoyal Guard\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EInterceptor G2\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EOlyset Plus\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EInterceptor\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ETanzania\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eexperimental hut trial\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Elong-lasting insecticidal net\u003C\/li\u003E\u003C\/ul\u003E\u003Ch3\u003ECompeting Interest Statement\u003C\/h3\u003E\u003Cp id=\u0022p-14\u0022\u003EThe authors have declared no competing interest.\u003C\/p\u003E\u003Ch3\u003EClinical Trial\u003C\/h3\u003E\u003Cp id=\u0022p-15\u0022\u003ENCT03554616\u003C\/p\u003E\u003Ch3\u003EClinical Protocols\u003C\/h3\u003E\u003Cp id=\u0022p-16\u0022\u003E\n\u003Ca href=\u0022https:\/\/bmjopen.bmj.com\/content\/11\/3\/e046664\u0022\u003Ehttps:\/\/bmjopen.bmj.com\/content\/11\/3\/e046664\u003C\/a\u003E\n\u003C\/p\u003E\u003Ch3\u003EFunding Statement\u003C\/h3\u003E\u003Cp id=\u0022p-17\u0022\u003EThis project is funded by the Bill and Melinda Gates Foundation through the Innovative Vector Control Consortium and under the global health trial, a jointly funded initiative from The Department of Health and Social Care, the Department for International Development, the Medical Research Council and the Wellcome Trust (Grant Ref: MR\/R006040\/1).\u003C\/p\u003E\u003Ch3\u003EAuthor Declarations\u003C\/h3\u003E\u003Cp id=\u0022p-18\u0022\u003EI confirm all relevant ethical guidelines have been followed, and any necessary IRB and\/or ethics committee approvals have been obtained.\u003C\/p\u003E\u003Cp id=\u0022p-19\u0022\u003EYes\u003C\/p\u003E\u003Cp id=\u0022p-20\u0022\u003EThe details of the IRB\/oversight body that provided approval or exemption for the research described are given below:\u003C\/p\u003E\u003Cp id=\u0022p-21\u0022\u003EThis protocol has received ethical approval from the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research (NIMR), Kilimanjaro Christian Medical University College (KCMUCO), and the London School of Hygiene and Tropical Medicine (LSHTM).\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003EAll necessary patient\/participant consent has been obtained and the appropriate institutional forms have been archived.\u003C\/p\u003E\u003Cp id=\u0022p-23\u0022\u003EYes\u003C\/p\u003E\u003Cp id=\u0022p-24\u0022\u003EI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\u003C\/p\u003E\u003Cp id=\u0022p-25\u0022\u003EYes\u003C\/p\u003E\u003Cp id=\u0022p-26\u0022\u003EI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\u003C\/p\u003E\u003Cp id=\u0022p-27\u0022\u003EYes\u003C\/p\u003E\u003Cdiv class=\u0022section fn-group\u0022 id=\u0022fn-group-1\u0022\u003E\u003Ch2\u003EFootnotes\u003C\/h2\u003E\u003Cul\u003E\u003Cli class=\u0022fn-others\u0022 id=\u0022fn-2\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003ELAM- \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Elouisa.messenger{at}lshtm.ac.uk\u003C\/span\u003E\u003C\/span\u003E, FWM \u2013 \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Efwmosha{at}gmail.com\u003C\/span\u003E\u003C\/span\u003E, EL- \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003EEliud.Lukole{at}lshtm.ac.uk\u003C\/span\u003E\u003C\/span\u003E, JFM - \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Ejfmosha{at}yahoo.com\u003C\/span\u003E\u003C\/span\u003E, TSC- \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Ethomas.churcher{at}imperial.ac.uk\u003C\/span\u003E\u003C\/span\u003E, ESS - \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Ee.sherrard-smith{at}imperial.ac.uk\u003C\/span\u003E\u003C\/span\u003E, MK-\u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003EManisha.Kulkarni{at}uottawa.ca\u003C\/span\u003E\u003C\/span\u003E, AM - \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Eamanjurano{at}yahoo.com\u003C\/span\u003E\u003C\/span\u003E, NP \u2013 \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Enatacha.protopopoff{at}lshtm.ac.uk\u003C\/span\u003E\u003C\/span\u003E and MR - \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Emark.rowland{at}lshtm.ac.uk\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-others\u0022 id=\u0022fn-3\u0022\u003E\u003Cp id=\u0022p-3\u0022\u003E\u003Cem\u003EFunding\u003C\/em\u003E. This project is funded by the Bill and Melinda Gates Foundation through the Innovative Vector Control Consortium and under the global health trial, a jointly funded initiative from The Department of Health and Social Care, the Department for International Development, the Medical Research Council and the Wellcome Trust (Grant Ref: MR\/R006040\/1).\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-42\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-106\u0022\u003ENot applicable.\u003C\/p\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-biorxiv-copyright\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022field field-name-field-highwire-copyright field-type-text field-label-inline clearfix\u0022\u003E\u003Cdiv class=\u0022field-label\u0022\u003ECopyright\u0026nbsp;\u003C\/div\u003E\u003Cdiv class=\u0022field-items\u0022\u003E\u003Cdiv class=\u0022field-item even\u0022\u003EThe copyright holder for this preprint is the author\/funder, who has granted medRxiv a license to display the preprint in perpetuity.\u003Cspan class=\u0022license-type\u0022\u003E It is made available under a \u003Ca href=\u0022http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/\u0022 class=\u0022\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003ECC-BY-ND 4.0 International license\u003C\/a\u003E.\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_SXHPyYQMndPSjH0oAPTy1xd0XLtmYCIziRIiNb0RJd8.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}